<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00075595</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000347378</org_study_id>
    <secondary_id>FRE-GERCOR-FOLFIRI3-C00-2</secondary_id>
    <secondary_id>EU-20333</secondary_id>
    <nct_id>NCT00075595</nct_id>
  </id_info>
  <brief_title>Fluorouracil, Leucovorin, and Irinotecan in Treating Patients With Recurrent or Refractory Metastatic Unresectable Colorectal Cancer</brief_title>
  <official_title>Phase II Study of 5FU/Folinic Acid and Irinotecan as Second or Third Line Treatment in Patients With Metastatic, Unresectable, Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and irinotecan, use&#xD;
      different ways to stop tumor cells from dividing so they stop growing or die. Giving more&#xD;
      than one chemotherapy drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving fluorouracil together with&#xD;
      leucovorin and irinotecan works in treating patients with recurrent or refractory metastatic&#xD;
      unresectable colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the time to progression and time to death from progression in patients with&#xD;
           recurrent or refractory metastatic unresectable colorectal cancer treated with&#xD;
           fluorouracil, leucovorin calcium, and irinotecan.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the objective response and stabilization rate in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the time to treatment failure in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the duration of response in patients treated with this regimen.&#xD;
&#xD;
        -  Determine overall survival rate in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the incidence of grade 3 or 4 toxicity in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
      Patients receive leucovorin calcium IV over 2 hours on day 1, irinotecan IV over 1 hour on&#xD;
      days 1 and 3, and fluorouracil IV continuously over 46 hours beginning on day 1. Courses&#xD;
      repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 78 patients will be accrued for this study within 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2002</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to death from progression</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stabilization rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3 or 4 toxicity</measure>
  </secondary_outcome>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed colorectal adenocarcinoma&#xD;
&#xD;
               -  Metastatic, unresectable disease&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  At least 1 unidimensionally measurable metastatic lesion at least 10 mm by spiral&#xD;
                  scan OR 20 mm by conventional scan&#xD;
&#xD;
               -  Evaluable disease&#xD;
&#xD;
               -  Evidence of disease (e.g., ascites or bone metastases) by imaging techniques&#xD;
&#xD;
          -  Progressive disease as defined by 1 of the following criteria:&#xD;
&#xD;
               -  Progressive disease while receiving first-line chemotherapy&#xD;
&#xD;
               -  Recurrent disease within 6 months after completing adjuvant chemotherapy&#xD;
&#xD;
          -  No symptomatic brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 80&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 3 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No uncontrolled angina&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No chronic diarrhea grade 2 or greater&#xD;
&#xD;
          -  No unresolved fully or partially obstructed intestine&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other underlying disease or medical condition that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  No other prior malignancy except curatively treated basal cell cancer or carcinoma in&#xD;
             situ of the cervix&#xD;
&#xD;
          -  No psychological, social, familial, or geographical condition that would preclude&#xD;
             study follow-up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior irinotecan&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 3 weeks since prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent clinical trial participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>May Mabro, MD</last_name>
    <affiliation>Hopital Foch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Drevon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospital Universitaire Hop Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Jean</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Joseph</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intercommunal Hospital</name>
      <address>
        <city>Montfermeil</city>
        <zip>93370</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Hospital of Paris</name>
      <address>
        <city>Neuilly Sur Seine</city>
        <zip>F-92202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat - Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Ste - Marie</name>
      <address>
        <city>Pontoise</city>
        <zip>95300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique De Courlancy</name>
      <address>
        <city>Reims</city>
        <zip>F-51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Armoricaine De Radiologie</name>
      <address>
        <city>Saint Brieuc</city>
        <zip>F-22015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de l'Orangerie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Medico-Chirurgical Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <study_first_submitted>January 9, 2004</study_first_submitted>
  <study_first_submitted_qc>January 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2004</study_first_posted>
  <last_update_submitted>January 3, 2009</last_update_submitted>
  <last_update_submitted_qc>January 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2009</last_update_posted>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

